Genassist Therapeutics recently announced that the Investigational New Drug (IND) application for GEN6050X, its globally first-in-class gene-editing drug for the treatment of Duchenne Muscular Dystrophy (DMD), has been approved by the U.S. Food and Drug Administration (FDA).

The research team led by Hans R. Schöler at the Max Planck Institute in Germany, in collaboration with Dr. Wu Guangming from Mingxun Biotechnology and other teams, published a study titled "Highly cooperative chimeric super-SOX: Inducing naive pluripotency beyond species boundaries" in the top-tier academic journal Cell Stem Cell. The paper provides an in-depth exploration of the aforementioned topic, with Dr. Wu Guangming from Mingxun Biotechnology contributing to a detailed analysis.

Ruizheng Gene (Suzhou) Co., Ltd. (referred to as "Ruizheng Gene" for short) recently announced that the U.S. Investigational New Drug (IND) application for its product ART001, which targets transthyretin amyloidosis (ATTR), has been approved. ART001 has thus become China’s first in vivo gene-editing drug based on non-viral vectors to obtain U.S. FDA clinical trial approval.